Topical versus low-dose systemic tranexamic acid in pediatric cardiac surgery: A randomized clinical study.
blood loss
congenital heart disease
perioperative management
tranexamic acid
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
01
08
2020
revised:
13
09
2020
accepted:
15
09
2020
pubmed:
30
9
2020
medline:
15
5
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
The current study aimed to compare the benefits of topical and low-dose systemic tranexamic acid administration in pediatric cardiac surgery. A total of 117 children undergoing cardiac surgery for congenital heart disease were assigned into three groups. Patients in the systemic group received 20 mg/kg Chest tube drainage was significantly lower in both topical and systemic groups than the control group, but it did not differ between the case groups. Blood products requirement did not show a difference between groups. Neurological or thromboembolic events did not variate among the groups, and no deaths occurred in this study. Topical or systemic tranexamic acid administration reduced postoperative blood loss effectively without adding an extra risk.
Substances chimiques
Antifibrinolytic Agents
0
Tranexamic Acid
6T84R30KC1
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3368-3373Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Van Der Linde D, Konings EE, Slager Ma, et al. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241-2247.
Kern FH, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:541-546.
Greeley WJ, Bushman GA, Kong DL, Oldham HN, Peterson MB. Effects of cardiopulmonary bypass on eicosanoid metabolism during pediatric cardiovascular surgery. J Thorac Cardiovasc Surg. 1988;95(5):842-849.
Ekert H, Gilchrist GS, Stanton R, Hammond D. Hemostasis in cyanotic congenital heart disease. J Pediatr. 1970;76(2):221-230.
Eaton MP. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg. 2008;106(4):1087-1100.
Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg. 2008;107(6):1783-1790.
Martin K, Breuer T, Gertler R, et al. Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2011;39(6):892-897.
Breuer T, Martin K, Wilhelm M, et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2009;35(1):167-171.
Khalil PN, Ismail M, Kalmar P, von Knobelsdorff G, Marx G. Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass. Thromb Haemost. 2004;92(09):568-574.
Tabuchi N, Boonstra PW. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1993;106(5):828-833.
De Bonis M, Cavaliere F, Alessandrini F, et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000;119(3):575-580.
Patel J, Prajapati M, Patel H, Gandhi H, Deodhar S, Pandya H. Topical and low-dose intravenous tranexamic acid in cyanotic cardiac surgery. Asian Cardiovasc Thorac Annals. 2017;25(2):118-122.
Bulutcu FS, Ozbek U, Polat B, Yalc ̧in Y, Karaci AR, Bayindir O. Which may be effective to reduce blood loss after cardiac oper- ations in cyanotic children: tranexamic acid, aprotinin or a combination? Paediatr Anaesth. 2005;15:41-46.
Chauhan S, Das SN, Bisoi A, Kale S, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18:141-143.
Chauhan S, Bisoi A, Kumar N, et al. Dose comparison of tranexamic acid in pediatric cardiac surgery. Asian Cardiovasc Thorac Ann. 2004;12:121-124.
Chauhan S, Bisoi A, Modi R, Gharde P, Rajesh MR. Tranexamic acid in paediatric cardiac surgery. Indian J Med Res. 2003;118:86-89.
Shimizu K, Toda Y, Iwasaki T, et al. Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial. J Anesth. 2011;25(6):823-830.
Zonis ZE, Seear M, Reichert C, Sett S, Allen C. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. J Thorac Cardiovasc Surg. 1996;111(5):982-987.
Reid RW, Zimmerman AA, Laussen PC, Mayer JE, Gorlin JB, Burrows FA. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg. 1997;84(5):990-996.
Hasegawa T, Oshima Y, Maruo A, et al. Intraoperative tranexamic acid in pediatric bloodless cardiac surgery. Asian Cardiovasc Thorac Annals. 2014;22(9):1039-1045.
Giordano R, Palma G, Poli V, et al. Tranexamic acid therapy in pediatric cardiac surgery: a single-center study. Ann Thorac Surg. 2012;94(4):1302-1306.
Furtmüller R, Schlag MG, Berger M, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a γ-aminobutyric acidA receptor antagonistic effect. J Pharmacol Exp Ther. 2002;301(1):168-173.